J Drugs Dermatol. 2023 Nov 1;22(11):e24-e28. doi: 10.36849/JDD.6999.
Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a rare and dangerous dermatologic emergency. It can have different presentations, especially in patients with multiple drug causes, and definitive management of SJS/TEN in these presentations remains unclear. Systemic corticosteroids, TNF inhibitors, and cyclosporine A are promising therapies.
In this case report, we present a 55-year-old man who developed SJS/TEN while on pembrolizumab and lamotrigine. The patient was treated with corticosteroids and a single dose of etanercept. After a one-week follow-up, the patient’s SJS/TEN had no new activity.
This literature review highlights how SJS/TEN may present differently in patients on immune checkpoint inhibitors. Treatments in these cases may vary from those with classic SJS/TEN. Specifically, etanercept given days late into the disease course is effective in speeding re-epithelialization and tapering of already given corticosteroids in classic SJS/TEN. J Drugs Dermatol. 2023;22(11):e24-e28 doi:10.36849/JDD.6999e.
史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症（SJS/TEN）是一种罕见且危险的皮肤科急症。它可能有不同的表现，特别是在由多种药物引起的患者中，这些表现的 SJS/TEN 的明确治疗方法仍不清楚。全身性皮质类固醇、TNF 抑制剂和环孢素 A 是有前途的治疗方法。
在本病例报告中，我们介绍了一名 55 岁男性，他在接受 pembrolizumab 和拉莫三嗪时发生 SJS/TEN。患者接受了皮质类固醇和单次依那西普治疗。一周后随访时，患者的 SJS/TEN 无新活动。
本文献复习强调了免疫检查点抑制剂患者的 SJS/TEN 可能表现不同。这些情况下的治疗可能与经典 SJS/TEN 不同。具体来说，在经典 SJS/TEN 中，在疾病过程中较晚给予依那西普可有效加速再上皮化并减少已给予的皮质类固醇的用量。J 皮肤病学杂志。2023;22(11)：e24-e28 doi：10.36849/JDD.6999e.
